Does the media favor ZNTL or VRCA?

In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 5 mentions for Verrica Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.25 beat Verrica Pharmaceuticals' score of -0.22 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor FENC or VRCA?

In the previous week, Adherex Technologies had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 6 mentions for Adherex Technologies and 5 mentions for Verrica Pharmaceuticals. Adherex Technologies' average media sentiment score of 0.22 beat Verrica Pharmaceuticals' score of -0.22 indicating that Adherex Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to VRCA or PALI?

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 2 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.22 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VNDA or VRCA?

In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 9 mentions for Vanda Pharmaceuticals and 5 mentions for Verrica Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of -0.09 beat Verrica Pharmaceuticals' score of -0.22 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Verrica Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend AMRN or VRCA?

Verrica Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 182.38%. Given Verrica Pharmaceuticals' higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer AMRN or VRCA?

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 2 mentions for Amarin. Amarin's average media sentiment score of -0.13 beat Verrica Pharmaceuticals' score of -0.22 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Verrica Pharmaceuticals (VRCA) Competitors

$5.14 +0.06 (+1.08%)

As of 10:04 AM Eastern

Compare

VRCA vs. ZNTL, FENC, PALI, VNDA, and AMRN

Should you buy Verrica Pharmaceuticals stock or one of its competitors? MarketBeat compares Verrica Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verrica Pharmaceuticals include Zentalis Pharmaceuticals (ZNTL), Adherex Technologies (FENC), Palisade Bio (PALI), Vanda Pharmaceuticals (VNDA), and Amarin (AMRN). These companies are all part of the "pharmaceuticals" industry.

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Zentalis Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Zentalis Pharmaceuticals' return on equity of -64.23% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-64.23%	-48.16%
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%

Verrica Pharmaceuticals has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.43	-$137.06M	-$1.95	N/A
Verrica Pharmaceuticals	$35.58M	2.48	-$17.89M	-$1.67	N/A

In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 5 mentions for Verrica Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.25 beat Verrica Pharmaceuticals' score of -0.22 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zentalis Pharmaceuticals currently has a consensus target price of $6.75, indicating a potential upside of 62.06%. Verrica Pharmaceuticals has a consensus target price of $14.50, indicating a potential upside of 182.38%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Zentalis Pharmaceuticals beats Verrica Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Adherex Technologies has a net margin of -17.12% compared to Verrica Pharmaceuticals' net margin of -102.84%. Adherex Technologies' return on equity of -43.87% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%

Adherex Technologies currently has a consensus price target of $15.40, indicating a potential upside of 37.57%. Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 182.38%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Adherex Technologies had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 6 mentions for Adherex Technologies and 5 mentions for Verrica Pharmaceuticals. Adherex Technologies' average media sentiment score of 0.22 beat Verrica Pharmaceuticals' score of -0.22 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Adherex Technologies has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Adherex Technologies has higher revenue and earnings than Verrica Pharmaceuticals. Adherex Technologies is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	8.79	-$9.74M	-$0.29	N/A
Verrica Pharmaceuticals	$35.58M	2.48	-$17.89M	-$1.67	N/A

Summary

Adherex Technologies beats Verrica Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Palisade Bio?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Palisade Bio has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Palisade Bio's return on equity of -36.79% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%
Palisade Bio	N/A	-36.79%	-34.34%

Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Palisade Bio. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 2 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.22 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Palisade Bio has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.48	-$17.89M	-$1.67	N/A
Palisade Bio	$250K	1,430.99	-$16.78M	-$1.01	N/A

Verrica Pharmaceuticals currently has a consensus price target of $14.50, suggesting a potential upside of 182.38%. Palisade Bio has a consensus price target of $9.00, suggesting a potential upside of 336.68%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Palisade Bio beats Verrica Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Vanda Pharmaceuticals presently has a consensus price target of $14.10, suggesting a potential upside of 185.43%. Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 182.38%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Vanda Pharmaceuticals is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has a net margin of -102.84% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%

In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 9 mentions for Vanda Pharmaceuticals and 5 mentions for Verrica Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of -0.09 beat Verrica Pharmaceuticals' score of -0.22 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Verrica Pharmaceuticals has lower revenue, but higher earnings than Vanda Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$215.72M	1.38	-$220.47M	-$4.63	N/A
Verrica Pharmaceuticals	$35.58M	2.48	-$17.89M	-$1.67	N/A

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Summary

Vanda Pharmaceuticals beats Verrica Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Amarin?

Amarin (NASDAQ:AMRN) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Amarin has a net margin of -14.56% compared to Verrica Pharmaceuticals' net margin of -102.84%. Amarin's return on equity of -0.20% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 2 mentions for Amarin. Amarin's average media sentiment score of -0.13 beat Verrica Pharmaceuticals' score of -0.22 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

22.3% of Amarin shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Verrica Pharmaceuticals has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.40	-$38.80M	-$0.99	N/A
Verrica Pharmaceuticals	$35.58M	2.48	-$17.89M	-$1.67	N/A

Verrica Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 182.38%. Given Verrica Pharmaceuticals' higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Verrica Pharmaceuticals beats Amarin on 9 of the 17 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCA vs. The Competition

Export

Metric	Verrica Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$88.65M	$11.86B	$7.02B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-3.09	788.48	269.90	24.97
Price / Sales	2.48	968.97	659.13	107.89
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	3.31	10.37	11.29	6.44
Net Income	-$17.89M	$2.77B	$3.45B	$347.50M
7 Day Performance	-2.19%	2.47%	3.56%	3.82%
1 Month Performance	-17.97%	-1.08%	-0.57%	-0.37%
1 Year Performance	-19.13%	191.49%	77.67%	23.81%

Verrica Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCA Verrica Pharmaceuticals	2.0472 of 5 stars	$5.14 +1.1%	$14.50 +182.4%	-20.0%	$88.65M	$35.58M	N/A	40	Gap Up
ZNTL Zentalis Pharmaceuticals	2.2597 of 5 stars	$4.65 -1.9%	$6.75 +45.2%	+193.1%	$337.42M	$67.43M	N/A	160	Earnings Report Analyst Downgrade Gap Up
FENC Adherex Technologies	3.879 of 5 stars	$9.59 +0.2%	$15.40 +60.6%	+38.9%	$335.27M	$44.64M	N/A	10	Upcoming Earnings Gap Down
PALI Palisade Bio	2.0347 of 5 stars	$1.94 +2.4%	$9.00 +363.9%	+167.1%	$328.93M	$250K	N/A	10	News Coverage
VNDA Vanda Pharmaceuticals	2.707 of 5 stars	$5.23 +2.5%	$14.30 +173.4%	+19.0%	$306.69M	$216.10M	N/A	290	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRCA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. ZNTL, FENC, PALI, VNDA, and AMRN

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Summary

How does Verrica Pharmaceuticals compare to Adherex Technologies?

Summary

How does Verrica Pharmaceuticals compare to Palisade Bio?

Summary

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Summary

How does Verrica Pharmaceuticals compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. ZNTL, FENC, PALI, VNDA, and AMRN

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Which has more volatility & risk, ZNTL or VRCA?

Do institutionals & insiders believe in ZNTL or VRCA?

Is ZNTL or VRCA more profitable?

Which has higher earnings & valuation, ZNTL or VRCA?

Does the media favor ZNTL or VRCA?

Do analysts prefer ZNTL or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Adherex Technologies?

Do insiders & institutionals believe in FENC or VRCA?

Is FENC or VRCA more profitable?

Do analysts rate FENC or VRCA?

Does the media favor FENC or VRCA?

Which has more volatility & risk, FENC or VRCA?

Which has higher earnings and valuation, FENC or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Palisade Bio?

Is VRCA or PALI more profitable?

Which has more risk and volatility, VRCA or PALI?

Does the media refer more to VRCA or PALI?

Do insiders & institutionals have more ownership in VRCA or PALI?

Which has preferable earnings and valuation, VRCA or PALI?

Do analysts prefer VRCA or PALI?

Summary

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Do analysts recommend VNDA or VRCA?

Is VNDA or VRCA more profitable?

Does the media favor VNDA or VRCA?

Do institutionals and insiders have more ownership in VNDA or VRCA?

Which has stronger valuation & earnings, VNDA or VRCA?

Which has more risk and volatility, VNDA or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Amarin?

Which has more risk & volatility, AMRN or VRCA?

Is AMRN or VRCA more profitable?

Does the media prefer AMRN or VRCA?

Do insiders & institutionals hold more shares of AMRN or VRCA?

Which has stronger earnings & valuation, AMRN or VRCA?

Do analysts recommend AMRN or VRCA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools